Alqahtani Saud, Alqahtani Ali, Alqahtani Taha, Al Fatease Adel, Almrasy Ahmed A
Department of Pharmacology, College of Pharmacy, King Khalid University Abha 62529 Saudi Arabia.
Department of Pharmaceutics, College of Pharmacy, King Khalid University Abha 62529 Saudi Arabia.
RSC Adv. 2025 May 15;15(21):16323-16336. doi: 10.1039/d5ra01945a.
Diabetes management has increasingly relied on dipeptidyl peptidase-4 inhibitors like linagliptin, creating a need for environmentally sustainable analytical methods to replace conventional chromatographic techniques that often involve complex sample preparation, organic solvent usage, and expensive instrumentation. A sensitive and selective "turn-off" fluorescence quenching method was developed and validated for the determination of linagliptin using eosin Y as the fluorescent probe. The spectral characteristics and sensing mechanisms were investigated using Stern-Volmer analysis, Job's method, and thermodynamic studies, revealing a static quenching process driven by the formation of a non-fluorescent 1 : 1 linagliptin-eosin Y complex with a high Stern-Volmer constant ( = 6.46 × 10 M). The influencing factors, including pH, buffer volume, eosin Y concentration, and incubation time, were optimized using a Box-Behnken experimental design. A significant reduced quadratic regression model was established, and the optimal conditions were found to be pH 5.25, buffer volume of 1 mL, eosin Y volume of 1.25 mL, and an incubation time of 5 min based on desirability function analysis that maximizes the quenching efficiency. The developed method demonstrated linearity in the range of 0.1-3.0 μg mL with a correlation coefficient of 0.9999, a limit of detection of 0.03 μg mL, and accuracy of 99.59 ± 1.360%, in accordance with ICH guidelines. Selectivity was confirmed by the lack of interference from common pharmaceutical excipients and endogenous plasma components. The eosin Y-based fluorescence quenching method was successfully applied for the determination of linagliptin in pharmaceutical dosage forms and spiked human plasma samples. Statistical comparison of the proposed method with the reported HPLC-UV method revealed comparable analytical performance as evident by non-significant differences in the accuracy and precision profiles as well as interval equivalence testing. Furthermore, a comprehensive assessment of the environmental impact and analytical practicality of the proposed method was conducted, confirming its "green" and "blue" analytical profile. These findings establish the eosin Y-based fluorescence quenching method as a viable and environmentally friendly alternative for the routine analysis of linagliptin in various pharmaceutical and bioanalytical applications shedding light on the potential of spectrofluorometric techniques in green analytical chemistry and bioanalysis.
糖尿病管理越来越依赖于诸如利格列汀之类的二肽基肽酶-4抑制剂,因此需要环境可持续的分析方法来取代传统的色谱技术,传统色谱技术通常涉及复杂的样品制备、有机溶剂使用和昂贵的仪器设备。开发并验证了一种灵敏且选择性的“关闭”荧光猝灭法,用于以曙红Y作为荧光探针测定利格列汀。使用斯特恩-沃尔默分析、乔布氏法和热力学研究对光谱特征和传感机制进行了研究,揭示了由形成具有高斯特恩-沃尔默常数( = 6.46 × 10 M)的非荧光1∶1利格列汀-曙红Y络合物驱动的静态猝灭过程。使用Box-Behnken实验设计对包括pH、缓冲液体积、曙红Y浓度和孵育时间在内的影响因素进行了优化。建立了显著简化的二次回归模型,并基于使猝灭效率最大化的合意函数分析,发现最佳条件为pH 5.25、缓冲液体积1 mL、曙红Y体积1.25 mL和孵育时间5分钟。所开发的方法在0.1 - 3.0 μg mL范围内呈线性,相关系数为0.9999,检测限为0.03 μg mL,准确度为99.59 ± 1.360%,符合国际人用药品注册技术协调会指南。常见药物赋形剂和内源性血浆成分无干扰,证实了其选择性。基于曙红Y的荧光猝灭法成功应用于药物剂型和加标人血浆样品中利格列汀的测定。将所提出的方法与报道的HPLC-UV法进行统计比较,结果表明分析性能相当,准确度和精密度曲线以及区间等效性测试中的非显著差异即为明证。此外,对所提出方法的环境影响和分析实用性进行了全面评估,证实了其“绿色”和“蓝色”分析特征。这些发现确立了基于曙红Y的荧光猝灭法作为一种可行且环境友好的替代方法,可用于各种药物和生物分析应用中利格列汀的常规分析,为荧光光谱技术在绿色分析化学和生物分析中的潜力提供了启示。